These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22172724)

  • 1. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
    Drost R; Bouwman P; Rottenberg S; Boon U; Schut E; Klarenbeek S; Klijn C; van der Heijden I; van der Gulden H; Wientjens E; Pieterse M; Catteau A; Green P; Solomon E; Morris JR; Jonkers J
    Cancer Cell; 2011 Dec; 20(6):797-809. PubMed ID: 22172724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    Drost R; Dhillon KK; van der Gulden H; van der Heijden I; Brandsma I; Cruz C; Chondronasiou D; Castroviejo-Bermejo M; Boon U; Schut E; van der Burg E; Wientjens E; Pieterse M; Klijn C; Klarenbeek S; Loayza-Puch F; Elkon R; van Deemter L; Rottenberg S; van de Ven M; Dekkers DH; Demmers JA; van Gent DC; Agami R; Balmaña J; Serra V; Taniguchi T; Bouwman P; Jonkers J
    J Clin Invest; 2016 Aug; 126(8):2903-18. PubMed ID: 27454287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
    Shakya R; Szabolcs M; McCarthy E; Ospina E; Basso K; Nandula S; Murty V; Baer R; Ludwig T
    Proc Natl Acad Sci U S A; 2008 May; 105(19):7040-5. PubMed ID: 18443292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
    Wang Y; Krais JJ; Bernhardy AJ; Nicolas E; Cai KQ; Harrell MI; Kim HH; George E; Swisher EM; Simpkins F; Johnson N
    J Clin Invest; 2016 Aug; 126(8):3145-57. PubMed ID: 27454289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    Ter Brugge P; Kristel P; van der Burg E; Boon U; de Maaker M; Lips E; Mulder L; de Ruiter J; Moutinho C; Gevensleben H; Marangoni E; Majewski I; Józwiak K; Kloosterman W; van Roosmalen M; Duran K; Hogervorst F; Turner N; Esteller M; Cuppen E; Wesseling J; Jonkers J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
    Moynahan ME
    Oncogene; 2002 Dec; 21(58):8994-9007. PubMed ID: 12483515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
    Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
    Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumorigenesis in mice carrying a truncating Brca1 mutation.
    Ludwig T; Fisher P; Ganesan S; Efstratiadis A
    Genes Dev; 2001 May; 15(10):1188-93. PubMed ID: 11358863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
    To C; Kim EH; Royce DB; Williams CR; Collins RM; Risingsong R; Sporn MB; Liby KT
    Cancer Prev Res (Phila); 2014 Jul; 7(7):698-707. PubMed ID: 24817481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and Characterization of a Brca1
    Hámori L; Kudlik G; Szebényi K; Kucsma N; Szeder B; Póti Á; Uher F; Várady G; Szüts D; Tóvári J; Füredi A; Szakács G
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
    Atipairin A; Canyuk B; Ratanaphan A
    J Biol Inorg Chem; 2011 Feb; 16(2):217-26. PubMed ID: 20967475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
    Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S
    Cancer Res; 2010 Feb; 70(4):1700-10. PubMed ID: 20145144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
    J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1.
    Kim SS; Cao L; Baek HJ; Lim SC; Li C; Wang RH; Xu X; Cho KH; Deng CX
    Cancer Res; 2009 Dec; 69(24):9291-300. PubMed ID: 19996295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of radiation therapy of
    Cho EJ; Kim JK; Baek HJ; Kim SE; Park EJ; Choi BK; Kim TH; Shin DH; Lim YK; Deng CX; Kim SS
    Int J Biol Sci; 2021; 17(3):689-701. PubMed ID: 33767581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
    Fabbro M; Schuechner S; Au WW; Henderson BR
    Exp Cell Res; 2004 Aug; 298(2):661-73. PubMed ID: 15265711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
    Hashizume R; Fukuda M; Maeda I; Nishikawa H; Oyake D; Yabuki Y; Ogata H; Ohta T
    J Biol Chem; 2001 May; 276(18):14537-40. PubMed ID: 11278247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.